Rare Disease Development Is a Different Kind of Problem
The clinical supply challenges in rare disease drug development are categorically different from those in standard pharmaceutical programmes. Patient populations are small, sometimes in the dozens rather than the thousands. The drug may be highly potent, genetically targeted, or manufactured using a technology platform with limited redundancy. Each individual dose can represent a disproportionately high cost relative to conventional therapeutics. And the consequence of a supply failure is not a delayed commercial shipment but a delayed patient dose that may have no alternative.
Building a resilient supply chain for a rare disease programme requires a different mindset and, often, a different type of CDMO partner.
The Specific Challenges of Rare Disease Supply
Small Batch Sizes
Standard GMP manufacturing processes and equipment are optimised for batch sizes that may be many times larger than what a rare disease programme requires. Running small batches efficiently, without compromising yield, analytical testing coverage, or the cost-per-dose economics, requires manufacturing processes specifically designed for small-scale production. Not all CDMOs have the equipment configuration and operational experience to do this well.
High-Value API Management
In a rare disease programme, the drug substance is often extremely expensive to produce. A failed GMP batch does not just mean a delay. It may mean a six-month wait for the next batch of API. Supply chain resilience therefore starts with process robustness: ensuring that the manufacturing process has sufficient design space that it succeeds reliably rather than at the limits of its capability.
Adaptive Trial Design Complexity
Many rare disease clinical trials use adaptive designs that allow the protocol to be modified based on interim data. From a supply chain perspective, this creates planning complexity: you need to hold enough clinical supply to support protocol expansions or changes, while avoiding overproduction of a high-cost drug for a small patient population. EMA guidance on adaptive trial designs acknowledges the particular challenges of adaptive studies and provides a framework for managing the interaction between trial design and drug supply.
Global Distribution to Low-Volume Sites
Phase II and III trials in rare diseases often require distribution to clinical sites across multiple countries, each receiving very small quantities of study drug. Standard clinical supply logistics assume larger shipments to more sites. Rare disease supply chains need solutions that can handle country-specific regulatory requirements, small-parcel cold chain, and the documentation requirements of each jurisdiction without the economies of scale that come with conventional clinical supply.
Rare Disease Supply Chain: Key Capability Requirements
| Capability | Why It Matters for Rare Disease | Ardena Capability |
| Small-batch GMP manufacturing | Patient populations may require fewer than 100 doses per batch | Available across Ghent, Pamplona, and Oss sites |
| HPAPI handling | Many rare disease drugs are highly potent | OEB 3-5 containment available at Pamplona |
| Lyophilisation | Common formulation strategy for biologic rare disease drugs | Available at Ghent |
| Clinical packaging and labelling | Complex country-specific requirements for small volumes | Available at Ghent and Assen |
| Stability management | Long-duration stability to support extended trial periods | GMP stability storage across multiple sites |
| CMC regulatory writing | Orphan designation has specific CMC implications | Integrated regulatory team, multi-jurisdictional experience |
The Orphan Drug Designation Dimension
Orphan Drug Designation (ODD), available through both the FDA and EMA, provides significant incentives for rare disease drug development, including fee waivers, regulatory assistance, and market exclusivity on approval. The designation also has CMC implications. The EMA’s ODD criteria include a requirement to justify the patient population size, and the CMC package for an orphan drug application may be reviewed with different data expectations than a standard application.
Ardena’s regulatory team has experience preparing CMC packages for programmes with orphan designation across both jurisdictions. Our related article on Preparing Module 3 of the CTD: A Practical Guide covers the CMC filing requirements relevant to rare disease programmes.
How Ardena Supports Rare Disease Programmes
Ardena’s manufacturing facilities are configured to handle small-batch GMP production efficiently, including for high-potency compounds at the Pamplona site and for complex injectables and lyophilised products at Ghent. The clinical supply team at Assen manages clinical packaging, labelling, and distribution across multiple markets for programmes with complex logistics requirements.
For rare disease programmes at any stage of development, Ardena’s integrated model means that the manufacturing strategy, the regulatory approach, and the clinical supply plan are developed together rather than sequentially, reducing the risk of misalignment that can cause delays at the worst possible moment.
